Axsome Therapeutics Inc

Common Name

Axsome Therapeutics

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

846

Ticker

AXSM

Exchange

NASDAQ/NMS

Website

www.axsome.com

Description

Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical... Show more

Financial Statements of Axsome Therapeutics

Below are the financial statements of Axsome Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in thousands of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	315,353^a	386,193^a
Accounts receivable, net	142,001^a	94,820^a
Inventories, net	15,732^a	15,135^a
Prepaid and other current assets	11,978^a	8,115^a
Total current assets	485,064^a	504,263^a
Assets	—	—
Equipment, net	584^a	846^a
Right-of-use asset - operating lease	5,383^a	6,772^a
Goodwill	12,042^a	12,042^a
Intangible asset, net	46,894^a	53,286^a
Non-current inventory and other assets	18,531^a	11,027^a
Total assets	568,498^a	588,236^a
Current liabilities	—	—
Accounts payable	71,997^a	40,679^a
Accrued expenses and other current liabilities	147,987^a	90,501^a
Operating lease liability, current portion	1,835^a	1,267^a
Contingent consideration, current	8,285^a	6,407^a
Total current liabilities	230,104^a	138,854^a
Liabilities and stockholders’ equity	—	—
Contingent consideration, non-current	91,680^a	73,300^a
Loan payable, long-term	180,710^a	178,070^a
Operating lease liability, long-term	6,046^a	7,035^a
Finance lease liability, long-term	2,943^a	0^a
Total liabilities	511,483^a	397,259^a
Stockholders’ equity	—	—
Preferred stock	0^a	0^a
Common stock	5^a	5^a
Additional paid-in capital	1,179,797^a	1,026,543^a
Accumulated deficit	-1,122,787^a	-835,571^a
Total stockholders’ equity	57,015^a	190,977^a
Total liabilities and stockholders’ equity	568,498^a	588,236^a

Verified Sources Behind Axsome Therapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Axsome Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. Axsome Therapeutics's 10-K 2024

Trace every data point back to Axsome Therapeutics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Axsome Therapeutics Inc

Financial Statements of Axsome Therapeutics

Verified Sources Behind Axsome Therapeutics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

ACADIA Pharmaceuticals Inc

Halozyme Therapeutics Inc

Blueprint Medicines Corp

Iovance Biotherapeutics Inc

Ultragenyx Pharmaceutical Inc

Insmed Inc